Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.

BACKGROUND Cytokeratins are specific markers of epithelial cancer cells in bone marrow. We assessed the influence of cytokeratin-positive micrometastases in the bone marrow on the prognosis of women with breast cancer. METHODS We obtained bone marrow aspirates from both upper iliac crests of 552 patients with stage I, II, or III breast cancer who underwent complete resection of the tumor and 191 patients with nonmalignant disease. The specimens were stained with the monoclonal antibody A45-B/B3, which binds to an antigen on cytokeratins. The median follow-up was 38 months (range, 10 to 70). The primary end point was survival. RESULTS Cytokeratin-positive cells were detected in the bone marrow specimens of 2 of the 191 control patients with nonmalignant conditions (1 percent) and 199 of the 552 patients with breast cancer (36 percent). The presence of occult metastatic cells in bone marrow was unrelated to the presence or absence of lymph-node metastasis (P=0.13). After four years of follow-up, the presence of micrometastases in bone marrow was associated with the occurrence of clinically overt distant metastasis and death from cancer-related causes (P<0.001), but not with locoregional relapse (P=0.77). Of 199 patients with occult metastatic cells, 49 died of cancer, whereas of 353 patients without such cells, 22 died of cancer-related causes (P<0.001). Among the 301 women without lymph-node metastases, 14 of the 100 with bone marrow micrometastases died of cancer-related causes, as did 2 of the 201 without bone marrow micrometastases (P<0.001). The presence of occult metastatic cells in bone marrow, as compared with their absence, was an independent prognostic indicator of the risk of death from cancer (relative risk, 4.17; 95 percent confidence interval, 2.51 to 6.94; P<0.001), after adjustment for the use of systemic adjuvant chemotherapy. CONCLUSIONS The presence of occult cytokeratin-positive metastatic cells in bone marrow increases the risk of relapse in patients with stage I, II, or III breast cancer.

[1]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[2]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Schlimok,et al.  Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. , 1996, Cancer genetics and cytogenetics.

[4]  V. Devita.  Breast Cancer Therapy: Exercising All Our Options , 1989 .

[5]  R. Coupland,et al.  Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer. , 1991, Canadian journal of surgery. Journal canadien de chirurgie.

[6]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[7]  T. Brümmendorf,et al.  Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D M Parkin,et al.  Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. , 1997, European journal of cancer.

[9]  H Stein,et al.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  J. Izbicki,et al.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.

[11]  K. Zedeler,et al.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. , 1997, The New England journal of medicine.

[12]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[13]  S. Ménard,et al.  Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. , 1990, European journal of cancer.

[14]  M. Speicher,et al.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. van Dalen,et al.  Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 Workshop , 1998, Tumor Biology.

[16]  E. Lengyel,et al.  Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  C. Redmond,et al.  Findings from NSABP protocol no. b‐04: Comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial‐central breast cancers , 1981, Cancer.

[18]  R. Coombes,et al.  Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study , 1999, The Lancet.

[19]  G. Riethmüller,et al.  Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. , 1992 .

[20]  G. Schlimok,et al.  Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients , 1992, The Lancet.

[21]  G. Schlimok,et al.  Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Bodmer,et al.  Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.

[23]  S. Ménard,et al.  Prognosis based on primary breast carcinoma instead of pathological nodal status. , 1994, British Journal of Cancer.

[24]  H. Stein,et al.  HUMAN LYMPHOID CELLS EXPRESS EPITHELIAL MEMBRANE ANTIGEN Implications for Diagnosis of Human Neoplasms , 1984, The Lancet.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  W. Eiermann,et al.  Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. , 1994, British Journal of Cancer.

[27]  P. Carroll,et al.  Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant , 1998, Cancer.

[28]  D. Cox.  Regression Models and Life-Tables , 1972 .

[29]  M L Lesser,et al.  Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Pantel,et al.  Prognostic significance of bone marrow micrometastases in patients with gastric cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Kasper,et al.  Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. , 1987, European journal of cancer & clinical oncology.

[32]  R. Cote,et al.  Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.

[33]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[34]  N. Le,et al.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. , 1997, The New England journal of medicine.

[35]  S. Hellman.  Stopping metastases at their source. , 1997, The New England journal of medicine.

[36]  T. Powles,et al.  Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. , 1981, British Journal of Cancer.